Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Natural Gas Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while United States Natural Gas Fund trades at $10.19. Which is the better fit depends on your goals.
| ALNY | UNG | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Energy |
52-Week High | $491.22 | $16.90 |
52-Week Low | $205.48 | $9.63 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
UNG trades at $10.20, up 0.59% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with mixed directional indicators. Recent news highlights natural gas price stability amid weather-driven demand fluctuations and ongoing discussions about futures versus equity exposure in the natural gas sector.
The outlook remains cautious with technical weakness offset by fundamental supply-demand dynamics. Investment opportunities exist in potential weather-driven price spikes, while risks include commodity volatility and the structural challenges of futures-based ETFs tracking spot prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
